<DOC>
	<DOCNO>NCT02585505</DOCNO>
	<brief_summary>Stem cell promise potential treating diabetes . However therapeutic outcome diabetic patient profoundly depend delivery pancreas . Our objective label stem cell PET tracer F18-FDG carry vivo cell track . The labeled stem cell give different route ( intravenous intraarterial ) tissue distribution study . Patients follow next 6 month . Glucagon stimulate C peptide measure baseline 6 month HOMA IR HOMA beta calculate .</brief_summary>
	<brief_title>Tissue Distribution F18-FDG Labeled ABMSCT Patients With Type2 Diabetes Mellitus</brief_title>
	<detailed_description>Our objective label stem cell PET tracer F18-FDG carry vivo cell track . The labeled stem cell give different route ( intravenous intraarterial ) tissue distribution study . Patients follow next 6 month . Glucagon stimulate C peptide measure baseline 6 month HOMA IR HOMA beta calculate .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>• Patients type 2 diabetes mellitus 30 65 year age . Duration diabetes ≥ 5 year . Failure triple OHA optimal dos { glimepiride ( 4 gm ) , metformin ( 22.5 gm ) pioglitazone ( 15mg ) } . Requiring insulin therapy last six month On stable dos insulin ( ≥0.4 IU/kg/day , Vildagliptin , metformin ( 2 gm ) , pioglitazone ( 15mg ) last three month . GAD antibody negative status . Patients type 1 diabetes mellitus secondary diabetes Patients serum creatinine &gt; 1.5 mg/dL Abnormal liver function test ( define value transaminases &gt; 3 time upper value normal serum bilirubin high normal reference value laboratory ) . History cholecystitis/ cholelithiasis/ cholecystectomy . Seropositivity HIV , HBsAg HCV . History myocardial infarction unstable angina cardiovascular event previous 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>